During the past decade, S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 4 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro" #1 collaborator was "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 5 trials as a collaborator, "CML Advocates Network" with 1 trials as a collaborator, "European Leukemia Net" with 1 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 1 trials as a collaborator and "Janssen Pharmaceutica" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro" are "Chronic Myeloid Leukemia" (5 trials), "Leukemia" (4 trials), "Acute Lymphoblastic Leukemia" (2 trials), "Acute Myeloid Leukemia" (2 trials) and "Myelodysplastic Syndromes" (2 trials). Many other conditions were trialed in "S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro" in a lesser frequency.

Most popular intervention types in "S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro" are "Drug" (26 trials), "Other" (9 trials), "Procedure" (2 trials), "Biological" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Imatinib" (2 trials), "Nilotinib" (2 trials), "Ponatinib" (2 trials), "dexamethasone" (2 trials) and "prednisone" (2 trials). Other intervention names were less common.

The vast majority of trials in "S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro" are 37 trials for "All" genders.

Currently, there are NaN active trials in "S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro". undefined are not yet recruiting, 2 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro, 0 "Phase 1" clinical trials were conducted, 22 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".